Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Human IL-10 produced in E. coli is a single, non-glycosylated polypeptide chain containing 160 amino acids and having a molecular mass of 18648 Dalton.
The ED50 as determined by the dose-dependant co-stimulation with murine IL-4 of MC-9 cells was found to be < 2ng/ml, corresponding to a Specific Activity of 1.0 x 106 IU/ mg.
Less than 0.1 ng/ug (IEU/ug) of rHuIL-10.
>98% as determined by SDS-PAGE , RP-HPLC and FPLC.
Lyophilized rHuIL-10 although stable at room temperature for 3 weeks, should be stored desiccated below -18oC. Upon reconstitution rHuIL-10 should be stored at 4oC between 2-7 days and for future use below -18oC. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Aliquot to avoid repeated freeze-thaw cycles.
It is recommended to reconstitute the lyophilized rHuIL-10 in sterile 18MΩ-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
PDB rendering based on 2H24.
In humans IL-10 is produced by activated CD8 (+) peripheral blood T-cells, by T-helper CD4 (+) T-cell clones (resembling Th0, Th1, and Th2) after both antigen-specific and polyclonal activation, by B-cell lymphomas, and by monocytes following cell activation by bacterial lipopolysaccharides and mast cells. B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of IL-10 into the conditioned medium. The synthesis of IL-10 by monocytes is inhibited by IL-4 and IL-10.
cytokine activity; interleukin-10 receptor binding; protein binding